192 related articles for article (PubMed ID: 32649663)
1. Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia.
Jin H; Tappenden P; Robinson S; Achilla E; Aceituno D; Byford S
PLoS One; 2020; 15(7):e0234996. PubMed ID: 32649663
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway.
Jin H; Tappenden P; Robinson S; Achilla E; MacCabe JH; Aceituno D; Byford S
Pharmacoeconomics; 2020 Jun; 38(6):537-555. PubMed ID: 32144726
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation.
Fleeman N; McLeod C; Bagust A; Beale S; Boland A; Dundar Y; Jorgensen A; Payne K; Pirmohamed M; Pushpakom S; Walley T; de Warren-Penny P; Dickson R
Health Technol Assess; 2010 Jan; 14(3):1-157, iii. PubMed ID: 20031087
[TBL] [Abstract][Full Text] [Related]
4. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.
Achilla E; McCrone P
Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
[TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
7. Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.
Kruse G; Wong BJ; Duh MS; Lefebvre P; Lafeuille MH; Fastenau JM
Pharmacoeconomics; 2015 Oct; 33(10):1049-67. PubMed ID: 25963579
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
9. Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies.
Jin H; Robinson S; Shang W; Achilla E; Aceituno D; Byford S
Pharmacoeconomics; 2021 Jul; 39(7):757-770. PubMed ID: 34013440
[TBL] [Abstract][Full Text] [Related]
10. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
[TBL] [Abstract][Full Text] [Related]
11. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies.
Greenhalgh J; Knight C; Hind D; Beverley C; Walters S
Health Technol Assess; 2005 Mar; 9(9):1-156, iii-iv. PubMed ID: 15774232
[TBL] [Abstract][Full Text] [Related]
12. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
Sun SX; Liu GG; Christensen DB; Fu AZ
Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
[TBL] [Abstract][Full Text] [Related]
13. Impact of atypical antipsychotics on quality of life in patients with schizophrenia.
Awad AG; Voruganti LN
CNS Drugs; 2004; 18(13):877-93. PubMed ID: 15521791
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of Schizophrenia.
Wang L; Shi F; Guan X; Xu H; Liu J; Li H
Front Public Health; 2021; 9():689123. PubMed ID: 34746073
[No Abstract] [Full Text] [Related]
15. Relationship between costs and symptoms in schizophrenia patients treated with antipsychotic medication: a review.
Sevy S; Visweswaraiah H; Mentschel C; Leucht S; Schooler NR
J Clin Psychiatry; 2004 Jun; 65(6):756-65. PubMed ID: 15291652
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review.
Henrique ICB; de Mendonça Lima T; de Melo DO; Aguiar PM
J Clin Pharm Ther; 2020 Feb; 45(1):1-15. PubMed ID: 31436857
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.
Haycox A
Pharmacoeconomics; 2005; 23 Suppl 1():3-16. PubMed ID: 16416758
[TBL] [Abstract][Full Text] [Related]
19. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ
Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
